In 2010, the NCCN issued a new prostate cancer guideline that called for active surveillance as the sole initial treatment for all men with very-low-risk and low-risk disease. The guideline was "ahead of its time," Dr. Mohler told the meeting last year. Now, the revised guidance has t...
3、转移性前列腺癌 Regional prostate cancer (Any T, Any N, M1) 普遍治疗原则同Regional prostate cancer
The article compares the guidelines of the National Comprehensive Cancer Network (NCCN) for treatment of prostate cancer with those of the American Urological Association (AUA) in 2010. The NCCN guidelines were aimed at helping urologists in caring for patients with this condition based on different...
The NCCN Prostate Cancer Panel also added new indications for existing agents, including the option of sipuleucel-T as second-line therapy. In addition, brachytherapy in combination with external beam radiation therapy with or without androgen deprivation therapy is now an alternative for patients with...
This systematic review to support the 2018 US Preventive Services Task Force Recommendation Statement on screening for prostate cancer summarizes
NICE. Prostate cancer: protocol for active surveillance. Implementing the NICE guideline on prostate cancer. 2014. https://www.nice.org.uk/guidance/cg175. National Health System (NHS). 2018. www.nhs.uk. NCCN. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. 2017. https://www...
Genetic testing, to identify pathogenic or likely pathogenic variants in prostate cancer, is valuable in guiding treatment decisions for men with prostate cancer and to inform cancer prevention and early detection options for their immediate blood relati
Cells treated with I mu M Aplidin for 24 h then killed by 100 Gy of radiation were toxic to untreated cells co-cultured with them. Conclusions: The cytotoxicity of Aplidin is independent of the oxygenation during treatment. Aplidin, or an active metabolite of Aplidin, is retained in the ...
The MMAI prognostic model had superior discrimination compared to the NCCN model for all outcomes, including 5-year distant metastasis (AUC of 0.83 vs 0.72, p-value < 0.001), 5-year biochemical failure (AUC of 0.69 vs 0.61, p-value < 0.001), 10-year prostate cancer-specific ...
Network (NCCN) Guidelines have updated recommendations for the consideration of adding second generation anti-androgens to androgen deprivation therapy (ADT) in men receiving radiation therapy (RT) for noncastrate locally advanced high and very high risk nonmetastatic or node positive prostate cancer. ...